￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

Oncology

Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Safety, efficacy and tolerability of alectinib in the treatment of ALK-positive non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Does alectinib have an effect on patients with lung cancer and brain metastases?

2025-10-19 11:44:20

Check Details
Treatment options for ALK-positive non-small cell lung cancer-Alectinib

2025-10-19 11:44:20

Check Details
The effectiveness of alectinib (Anshengsha) in the first-line treatment of lung cancer

2025-10-19 11:44:20

Check Details
Does nivolumab need to be infused away from light?

2025-10-19 11:44:20

Check Details
FDA-approved first-line treatment drug for AKL: second-generation ALK inhibitor alectinib (Ansantsa)

2025-10-19 11:44:20

Check Details
What is the efficacy of Xalkori in the first-line treatment of advanced non-small cell lung cancer? Any new breakthroughs?

2025-10-19 11:44:20

Check Details
Effect data of nivolumab in the treatment of metastatic non-small cell lung cancer

2025-10-19 11:44:20

Check Details
[Very Important] Precautions for lung cancer patients taking Xalkore (crizotinib)

2025-10-19 11:44:20

Check Details
Analysis of the efficacy of Erlotinib Hydrochloride Tablets in the second-line treatment of non-small cell lung cancer

2025-10-19 11:44:20

Check Details
To save money when buying medicines, refer to the 2021 medical insurance reimbursement conditions for Xalkori (crizotinib)

2025-10-19 11:44:20

Check Details
Any progress? Analysis of the effectiveness and safety of Xalkori in the treatment of ALK-positive non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Category
相关知识